Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 9/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 5/20 | 0.33 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6630676 | 0.90 | HTT (0.35) | F2RHTTSLC2A1DCPSTP53 | |
| SCHEMBL6795053 | 0.83 | F2R (0.48) | F2RHTTDCPSTP53MAPT | |
| SCHEMBL6630874 | 0.78 | TRPM5 (0.35) | HTTMAPT | |
| SCHEMBL6631095 | 0.76 | DCPS (0.38) | F2RHTTDCPS | |
| SCHEMBL6630460 | 0.69 | CYP1A2 (0.38) | F2RTP53MAPT | |
| SCHEMBL21121770 | 0.64 | SMN1; SMN2 (0.48) | HTTTP53MAPT | |
| Bromide SCHEMBL21121865 | 0.63 | SMN1; SMN2 (0.47) | HTTTP53MAPT | |
| SCHEMBL10197977 | 0.58 | HTR2C (0.68) | — | |
| SCHEMBL24165041 | 0.58 | SLC2A1 (0.72) | F2RSLC2A1 | |
| SCHEMBL22048288 | 0.57 | SLC6A2 (0.46) | HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370560-B1 | AMINOMETHYL-PYRROLOQUINAZOLINE COMPOUNDS AS THROMBIN RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2004-11-10 | — | — | EP | claimed |
| US-6740657-B2 | FOR EXAMPLE, N3-CYCLOPROPYL-7-((2,6-DICHLOROPHENYL)METHYL)-9-((DIMETHYLAMINO)METHYL)-7H -PYRROLO(3,2-F) QUINAZOLINE-1,3-DIAMI NE; TREATING CARDIOVASCULAR DISORDERS, RESTENOSIS, THROMBOSIS, AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-05-25 | — | — | US | claimed |
| US-20020160963-A1 | Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-31 | — | — | US | claimed |
| EP-1370560-B1 | AMINOMETHYL-PYRROLOQUINAZOLINE COMPOUNDS AS THROMBIN RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160963-A1 | Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists | F2R, F2RL1, F2RL3 | F2R 1/4885HTT 2936/4885SLC2A1 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.